Category: Latest News
-

Teledyne Technologies shares climb after strong second-quarter earnings beat and raised outlook (NYSE:TDY)
Record quarterly performance drives earnings beat Teledyne Technologies Incorporated (NYSE:TDY) reported better-than-expected second-quarter 2026 results on Wednesday, as record orders, revenue and operating profit helped the company surpass Wall Street forecasts and lift its full-year guidance. The aerospace and defence technology company posted adjusted earnings per share of $6.28, comfortably ahead of the analyst consensus…
-

CME Group shares edge higher after second-quarter earnings beat expectations (NASDAQ:CME)
Earnings top forecasts despite slight revenue miss CME Group Inc. (NASDAQ:CME) reported second-quarter 2026 results on Wednesday, delivering adjusted earnings that exceeded Wall Street expectations, although revenue came in slightly below analysts’ forecasts. The derivatives exchange operator posted adjusted earnings per share of $2.99, ahead of the consensus estimate of $2.95. Revenue totaled $1.71 billion,…
-

First BanCorp shares edge higher after second-quarter earnings top expectations (NYSE:FBP)
Strong quarterly results exceed Wall Street forecasts First BanCorp. (NYSE:FBP) reported better-than-expected second-quarter 2026 results on Wednesday, as higher net interest income and continued loan growth helped drive a solid increase in profitability. The bank posted adjusted earnings per share of $0.62, surpassing analysts’ consensus estimate of $0.54 by $0.08. Revenue reached $264.86 million, slightly…
-

Adtran shares tumble after company cuts second-quarter revenue outlook (NASDAQ:ADTN)
Customer project delay prompts weaker forecast Adtran Holdings (NASDAQ:ADTN) shares dropped 14% on Wednesday after the networking equipment provider lowered its preliminary second-quarter 2026 revenue outlook, citing a delay to a major customer project. The company now expects second-quarter revenue to be between $280.0 million and $282.0 million, below its previous guidance of $283.0 million…
-

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
Discounted share sale weighs on stock Dyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million. The offering was priced at $20.50 per share, representing a discount of about 14% to Tuesday’s closing price of $23.83, contributing to the…
-

Iridium shares edge higher despite second-quarter earnings miss (NASDAQ:IRDM)
Revenue beats expectations as acquisition costs weigh on profit Iridium Communications Inc. (NASDAQ:IRDM) reported second-quarter 2026 results on Wednesday that topped revenue expectations but fell short on earnings, as costs related to its pending acquisition by Rocket Lab weighed on profitability. The satellite communications company posted adjusted earnings per share of $0.09, below the analyst…
-

Old National Bancorp shares climb after second-quarter earnings exceed forecasts (NASDAQ:ONB)
Record quarterly profit tops Wall Street expectations Old National Bancorp (NASDAQ:ONB) reported stronger-than-expected second-quarter 2026 results on Wednesday, driven by higher revenue, solid loan growth and record profitability. The bank posted adjusted earnings per share of $0.65, ahead of the analyst consensus estimate of $0.63. Revenue on a fully taxable equivalent basis totaled $740.06 million,…
-

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)
New lymphoma results support development programme Curis, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and raised enrollment expectations for its Chronic Lymphocytic Leukemia (CLL) study. Updated findings from the TakeAim Lymphoma trial showed an overall response rate…
-

Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT)
New survival data supports ivonescimab treatment Summit Therapeutics Inc. (NASDAQ:SMMT) shares gained 3% on Wednesday after the company released updated overall survival data from its global Phase III HARMONi trial evaluating ivonescimab in combination with chemotherapy for advanced lung cancer. The study enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer…
-

Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
Late-stage studies achieve all primary and secondary goals Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares jumped 18% on Wednesday after the company announced positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia. Both studies successfully met their primary endpoint of reducing triglyceride levels compared with placebo, while…